Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

BACKGROUND AND OBJECTIVE: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits extend to patients without diabetes. Limited phar...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C. J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z. I., Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016788/
https://www.ncbi.nlm.nih.gov/pubmed/33587286
http://dx.doi.org/10.1007/s40262-020-00956-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016788/
https://www.ncbi.nlm.nih.gov/pubmed/33587286
http://dx.doi.org/10.1007/s40262-020-00956-1

Ejemplares similares